Share

Deals in brief

Powered by

Sanofi agrees to acquire Principia Biopharma for $3.68bn

Sanofi has signed a definitive agreement to acquire all outstanding shares of US-based Principia Biopharma for around $3.68bn, or $100 per share, in cash.

Principia is a biopharmaceutical firm engaged in the development of therapies for immune-mediated diseases with unmet medical needs.

The company’s Bruton tyrosine kinase (BTK) inhibitors will boost Sanofi’s research and development (R&D) efforts across autoimmune diseases area.

Principia BTK inhibitor portfolio is based on the company’s Tailored Covalency platform, used to design reversible covalent and irreversible covalent small molecule inhibitors.

BTK is related to the signalling pathways of innate and adaptive cell types of the immune system. Inhibition of these signalling processes could potentially halt inflammation and tissue destruction caused autoimmune diseases, as well as target certain underlying pathophysiology.

In 2017, Sanofi signed an exclusive, global licence agreement to develop and commercialise Principia’s BTK inhibitor ‘168 in multiple sclerosis and other central nervous system diseases.

The acquisition will help Sanofi expand the development programme of BTK inhibitor ‘168 to indications other than central nervous system diseases. Currently, the drug candidate is being assessed in a Phase IIb clinical trial for multiple sclerosis.

Also, Principia is evaluating oral BTK inhibitor Rilzabrutinib in a Phase III programme for the treatment of moderate to severe pemphigus, a rare autoimmune disease. Another Phase III programme for immune thrombocytopenia is planned for the end of this year. An ongoing Phase II programme is also ongoing for IgG4-related diseases.

A topical BTK inhibitor, PRN473, is undergoing Phase I trials for immune-mediated diseases that could be treated with localised application to the skin.

Boards of directors of both companies approved the acquisition. It is subject to customary closing conditions and should close in the fourth quarter of this year. After closing of the transaction, a wholly-owned subsidiary of Sanofi will merge with Principia.

UNION therapeutics licences drug technology from TFF Pharmaceuticals

SK bioscience partners with Novavax on Covid-19 vaccine

South Korea-based SK bioscience has entered a development and supply agreement for Novavax Covid-19 vaccine candidate, NVX-CoV2373.

The company intends to supply the vaccine to global markets, including COVAX Facility. 

SK bioscience and Novavax also signed a letter of intent with the Republic of Korea’s Ministry of Health and Welfare to facilitate equitable access to the vaccine worldwide, as well as in South Korea.

Biological E to manufacture Janssen’s Covid-19 vaccine

India-based pharmaceutical company Biological E has signed an agreement with Johnson & Johnson (J&J) unit Janssen Pharmaceutica to manufacture J&J’s Covid-19 vaccine candidate, Ad26.COV2.S.

Under the deal, Biological E will boost production capacities for drug substance and drug product of the vaccine candidate currently in Phase I/IIa clinical trials.

Ligand Pharmaceuticals agrees to acquire Pfenex for $516m

Ligand Pharmaceuticals has entered into a definitive agreement to acquire development and licensing biotechnology firm Pfenex in a deal valued at approximately $516m.

Under the agreement, Ligand will buy all outstanding shares of Pfenex for $12 per share in cash or $438m in equity value on a fully diluted basis.

Celleron licenses cancer drug emactuzumab from Roche

UK-based Celleron Therapeutics has entered an exclusive licensing agreement with Roche for global rights to the clinical development, manufacturing and commercialisation of cancer drug, emactuzumab.

The deal is part of Celleron’s focus on drug development for cancer patients.

Emactuzumab is an experimental monoclonal antibody that targets and decreases macrophages in the tumor tissue.

GeneCentric Therapeutics signs research alliance with Janssen

GeneCentric Therapeutics and Janssen Research & Development have formed a research alliance focused on RNA-based drug response biomarkers for non-muscle invasive bladder cancer.

The partners will leverage GeneCentric’s advanced RNA-based molecular profiling platform to gain better insights into potential signatures of disease progression and drug response to standard of care therapy.

Share this article

Go to article: Home | Pause for thoughtGo to article: In this issueGo to article: NSFGo to article: ContentsGo to article: Datwyler Company Insight Go to article: DatwylerGo to article: NewsGo to article: BaxterGo to article: Covid-19 executive briefing by GlobalDataGo to article: ELPRO Monitoring SolutionsGo to article: Abivax’s ABX464 enticing in theory for Covid-19 but mechanism, trial design issues belie potential for successGo to article: Abiomed’s Impella receives FDA Emergency Use Authorization during Covid-19Go to article: FargoGo to article: Disruptions to global oncology trials have fallen to a three-month lowGo to article: MimotopesGo to article: AstraZeneca/Oxford University and CanSino publish promising Covid-19 vaccine cliGo to article: Biotech IPO valuation relies on data to enter capital markets during Covid-19 paGo to article: Nelson LabsGo to article: The pharma industry briefingGo to article: Pfeiffer VacuumGo to article: A century of cultures: celebrating the world’s oldest lab culture collectionGo to article: SkyepharmaGo to article: Gut feeling: exploring the therapeutic potential of the gut-brain axisGo to article: OptelGo to article: Crabby concoctions: why pharma’s thirst for crustacean blood is up for debateGo to article: Air FranceGo to article: Debunking myths about puberty blockers for transgender childrenGo to article: MicronovaGo to article: Hiring from home: pharma recruitment in the age of Covid-19 Go to article: Nipro PharmapackagingGo to article: Q&A: breaking new ground in pharma packaging with HoneywellGo to article: WipotecGo to article: Treatment-resistant rare diseases: exploring landmark drug approvals in 2020Go to article: VEGA Company Insight Go to article: VEGA AustraliaGo to article: Modernising pharma patents: can AI be an inventor?Go to article: ILC Dover Go to article: Boosting agility to accelerate project timescales Go to article: Scandinavian HealthGo to article: Doing the right thing: the enhanced case for complianceGo to article: Deals in brief powered by GlobalDataGo to article: The key list powered by GlobalDataGo to article: Global markets and indices powered by GlobalDataGo to article: Macro-economic indicators (1 of 2) powered by GlobalDataGo to article: Macro-economic indicators (2 of 2) powered by GlobalDataGo to article: EventsGo to article: Next issue